American Pharmaceutical Security Act
The source supplies the latest action, but no lifecycle stage.
Latest action (6 Aug 2026): Read twice and referred to the Committee on Finance.
What this bill does
S. 5297 would direct the Administrator of the Centers for Medicare & Medicaid Services (CMS) to prepare and submit a report examining how existing coverage and reimbursement authorities could be used to protect the U.S. market for active pharmaceutical ingredients (APIs) and key starting materials — the raw chemical components used to manufacture prescription drugs. Beyond this reporting requirement, the specific contents, findings, or any policy changes the bill would mandate are not yet known, since the full legislative text has not been published.
The bill would primarily affect CMS, which would bear the reporting obligation, and by extension it touches the pharmaceutical manufacturing supply chain, since APIs and starting materials are core inputs to drug production. Because the bill's substantive provisions are not yet public, it is not possible to say with certainty how patients, drug manufacturers, or other stakeholders would be affected in practice.
The bill was introduced in the Senate on August 6, 2026, by Senator Adam Schiff (D-CA), and its status is currently "Introduced." The next steps would typically involve committee assignment and review; no further action has yet been recorded. Once the full text becomes available, a more detailed summary of its specific requirements and effects can be provided.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
6 Aug 2026
Read twice and referred to the Committee on Finance.
Common questions
- What does S. 5297 do?
- S. 5297 would direct the Administrator of the Centers for Medicare & Medicaid Services (CMS) to prepare and submit a report examining how existing coverage and reimbursement authorities could be used to protect the U.S. market for active pharmaceutical ingredients (APIs) and key starting materials — the raw chemical components used to manufacture prescription drugs. Beyond this reporting requirement, the specific contents, findings, or any policy changes the bill would mandate are not yet known, since the full legislative text has not been published. The bill would primarily affect CMS, which would bear the reporting obligation, and by extension it touches the pharmaceutical manufacturing supply chain, since APIs and starting materials are core inputs to drug production. Because the bill's substantive provisions are not yet public, it is not possible to say with certainty how patients, drug manufacturers, or other stakeholders would be affected in practice. The bill was introduced in the Senate on August 6, 2026, by Senator Adam Schiff (D-CA), and its status is currently "Introduced." The next steps would typically involve committee assignment and review; no further action has yet been recorded. Once the full text becomes available, a more detailed summary of its specific requirements and effects can be provided.
- Has S. 5297 become law?
- The source does not supply a confirmed lifecycle stage for S. 5297. Check the latest action and official source below.
- Who sponsored S. 5297?
- S. 5297 was sponsored by Sen. Schiff, Adam B. [D-CA] (D-CA), with 1 cosponsor.
- What's the latest action on S. 5297?
- Read twice and referred to the Committee on Finance. (6 Aug 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
More bills from Sen. Schiff, Adam B. [D-CA]
Food for Thought Act of 2026
Hot Meals for College Students Act of 2026
A bill to direct the Secretary of Agriculture to improve safety standards for wildland firefighters.
Water Cyber Shield Act of 2026
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.